» Articles » PMID: 24456537

Frequency of IFNγ-producing T Cells Correlates with Seroreactivity and Activated T Cells During Canine Trypanosoma Cruzi Infection

Overview
Journal Vet Res
Publisher Biomed Central
Date 2014 Jan 25
PMID 24456537
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccines to prevent Trypanosoma cruzi infection in humans or animals are not available, and in many settings, dogs are an important source of domestic infection for the insect vector. Identification of infected canines is crucial for evaluating peridomestic transmission dynamics and parasite control strategies. As immune control of T. cruzi infection is dependent on humoral and cell-mediated immune responses, we aimed to define a serodiagnostic assay and T cell phenotypic markers for identifying infected dogs and studying the canine T. cruzi-specific immune response. Plasma samples and peripheral blood mononuclear cells (PBMCs) were obtained from forty-two dogs living in a T. cruzi-endemic region. Twenty dogs were known to be seropositive and nine seronegative by conventional serologic tests two years prior to our study. To determine canine seroreactivity, we tested sera or plasma samples in a multiplex bead array against eleven recombinant T. cruzi proteins. Ninety-four percent (17/18) of dogs positive by multiplex serology were initially positive by conventional serology. The frequency of IFNγ-producing cells in PBMCs responding to T. cruzi correlated to serological status, identifying 95% of multiplex seropositive dogs. Intracellular staining identified CD4+ and CD8+ T cell populations as the sources of T. cruzi lysate-induced IFNγ. Low expression of CCR7 and CD62L on CD4+ and CD8+ T cells suggested a predominance of effector/effector memory T cells in seropositive canines. These results are the first, to our knowledge, to correlate T. cruzi-specific antibody responses with T cell responses in naturally infected dogs and validate these methods for identifying dogs exposed to T. cruzi.

Citing Articles

Animal models for exploring Chagas disease pathogenesis and supporting drug discovery.

Khan A, Taylor M, Fortes Francisco A, Jayawardhana S, Atherton R, Olmo F Clin Microbiol Rev. 2024; 37(4):e0015523.

PMID: 39545730 PMC: 11629624. DOI: 10.1128/cmr.00155-23.


Validation of a multiplex microsphere immunoassay for detection of antibodies to in dogs.

Rodriguez C, Busselman R, Shen H, Saunders A, Tarleton R, Hamer S J Vet Diagn Invest. 2023; 35(6):704-709.

PMID: 37670473 PMC: 10621557. DOI: 10.1177/10406387231198525.


ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas' disease.

Castro J, Brito R, Hojo-Souza N, Azevedo B, Salazar N, Ferreira C NPJ Vaccines. 2023; 8(1):81.

PMID: 37258518 PMC: 10231858. DOI: 10.1038/s41541-023-00676-0.


Prophylactic low-dose, bi-weekly benznidazole treatment fails to prevent Trypanosoma cruzi infection in dogs under intense transmission pressure.

Bustamante J, Padilla A, White B, Auckland L, Busselman R, Collins S PLoS Negl Trop Dis. 2022; 16(10):e0010688.

PMID: 36315597 PMC: 9648846. DOI: 10.1371/journal.pntd.0010688.


High variation in immune responses and parasite phenotypes in naturally acquired Trypanosoma cruzi infection in a captive non-human primate breeding colony in Texas, USA.

Padilla A, Yao P, Landry T, Cooley G, Mahaney S, Ribeiro I PLoS Negl Trop Dis. 2021; 15(3):e0009141.

PMID: 33788859 PMC: 8041201. DOI: 10.1371/journal.pntd.0009141.


References
1.
Reithinger R, Ceballos L, Stariolo R, Davies C, Gurtler R . Extinction of experimental Triatoma infestans populations following continuous exposure to dogs wearing deltamethrin-treated collars. Am J Trop Med Hyg. 2006; 74(5):766-71. PMC: 2633875. View

2.
Stuart K, Brun R, Croft S, Fairlamb A, Gurtler R, McKerrow J . Kinetoplastids: related protozoan pathogens, different diseases. J Clin Invest. 2008; 118(4):1301-10. PMC: 2276762. DOI: 10.1172/JCI33945. View

3.
Tarleton R, Koller B, LaTour A, Postan M . Susceptibility of beta 2-microglobulin-deficient mice to Trypanosoma cruzi infection. Nature. 1992; 356(6367):338-40. DOI: 10.1038/356338a0. View

4.
Aparicio-Burgos J, Ochoa-Garcia L, Zepeda-Escobar J, Gupta S, Dhiman M, Martinez J . Testing the efficacy of a multi-component DNA-prime/DNA-boost vaccine against Trypanosoma cruzi infection in dogs. PLoS Negl Trop Dis. 2011; 5(5):e1050. PMC: 3098890. DOI: 10.1371/journal.pntd.0001050. View

5.
Michailowsky V, Silva N, Rocha C, Vieira L, Lannes-Vieira J, Gazzinelli R . Pivotal role of interleukin-12 and interferon-gamma axis in controlling tissue parasitism and inflammation in the heart and central nervous system during Trypanosoma cruzi infection. Am J Pathol. 2001; 159(5):1723-33. PMC: 3277321. DOI: 10.1016/s0002-9440(10)63019-2. View